Results 41 to 50 of about 18,392,427 (194)

Entinostat-Bortezomib Hybrids against Multiple Myeloma

open access: yesMolecules, 2023
Although proteasome inhibitors have emerged as the therapeutic backbone of multiple myeloma treatment, patients often relapse and become drug refractory. The combination between proteasome and histone deacetylase inhibitors has shown to be more efficient
Angelica Ferro   +4 more
doaj   +1 more source

Dissecting the roles of histone deacetylase 1 and 2 in the hematopoietic system [PDF]

open access: yes, 2008
Reversible histone acetylation on lysine residues has been intensively studied as an epigenetic mark for gene activation in a variety of eukaryotes. Histone deacetylases (HDACs) act to repress gene expression by removing acetyl groups from histones and ...
Yamaguchi, Teppei
core   +1 more source

Droxinostat, a Histone Deacetylase Inhibitor, Induces Apoptosis in Hepatocellular Carcinoma Cell Lines via Activation of the Mitochondrial Pathway and Downregulation of FLIP

open access: yesTranslational Oncology, 2016
Background: The current chemotherapeutic outcomes for hepatocellular carcinoma (HCC) are not encouraging, and long-term survival of this patient group remains poor.
Jing Liu   +9 more
doaj   +1 more source

Role for histone deacetylase 3 in maintenance of genome stability [PDF]

open access: yesCell Cycle, 2011
Histone deacetylase 3 (Hdac3) is the catalytic enzyme in a transcriptional repression complex that contains the nuclear hormone co-repressors (N-CoR or SMRT). As such, Hdac3 has largely been studied in the context of gene regulation of targets of nuclear hormone receptors and other transcription factors that recruit these corepressors.
Srividya, Bhaskara, Scott W, Hiebert
openaire   +2 more sources

Histone deacetylase 2 is required for chromatin condensation and subsequent enucleation of cultured mouse fetal erythroblasts

open access: yesHaematologica, 2010
Background During the final stages of differentiation of mammalian erythroid cells, the chromatin is condensed and enucleated. We previously reported that Rac GTPases and their downstream target, mammalian homolog of Drosophila diaphanous 2 (mDia2), are ...
Peng Ji   +4 more
doaj   +1 more source

Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer [PDF]

open access: yes, 2008
Background Enhanced activity of histone deacetylases (HDAC) is associated with more aggressive tumour behaviour and tumour progression in various solid tumours.
Dietel Manfred   +21 more
core   +1 more source

Histone deacetylases facilitate the accurate repair of broken forks

open access: yesMolecular & Cellular Oncology, 2020
We have recently uncovered that loss of the yeast histone deacetylases Rpd3 (Reduced Potassium Dependency 3) and Hda1 (Histone DeAcetylase 3) affects the cohesion between sister chromatids thus impairing repair of DNA damage at replication forks and ...
Belén Gómez-González   +2 more
doaj   +1 more source

The deacetylase HDAC6 is an essential component of stress granules and plays a critical role in the cellular response to stress [PDF]

open access: yes, 2007
The reversible acetylation of histones has a critical role in transcriptional regulation. Likewise reversible acetylation of non-histones proteins is also important for other cellular processes.
Kwon, So Hee
core   +1 more source

Histone Deacetylase 3 Is Necessary for Proper Brain Development [PDF]

open access: yesJournal of Biological Chemistry, 2014
The functional role of histone deacetylase 3 (HDAC3) in the developing brain has yet to be elucidated. We show that mice lacking HDAC3 in neurons and glia of the central nervous system, Nes-Cre/HDAC3 conditional KO mice, show major abnormalities in the cytoarchitecture of the neocortex and cerebellum and die within 24 h of birth.
Jordan, Norwood   +3 more
openaire   +2 more sources

Resistance after chronic application of the HDAC-inhibitor valproic acid is associated with elevated Akt activation in renal cell carcinoma in vivo [PDF]

open access: yes, 2013
Targeted drugs have significantly improved the therapeutic options for advanced renal cell carcinoma (RCC). However, resistance often develops, negating the benefit of these agents.
Eva Juengel   +13 more
core   +2 more sources

Home - About - Disclaimer - Privacy